Shares of VBI Vaccines Inc (NASDAQ:VBIV) gapped down before the market opened on Wednesday . The stock had previously closed at $0.84, but opened at $0.86. VBI Vaccines shares last traded at $0.83, with a volume of 91,401 shares trading hands.
A number of equities analysts have recently commented on the stock. Raymond James initiated coverage on shares of VBI Vaccines in a research report on Thursday, November 14th. They issued an “outperform” rating and a $3.00 price target on the stock. Zacks Investment Research downgraded shares of VBI Vaccines from a “buy” rating to a “hold” rating in a report on Wednesday, August 21st. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $3.81.
The company has a current ratio of 1.88, a quick ratio of 1.84 and a debt-to-equity ratio of 0.01. The firm has a market cap of $160.13 million, a price-to-earnings ratio of -0.88 and a beta of 0.79. The firm has a 50-day moving average of $0.63 and a two-hundred day moving average of $0.88.
VBI Vaccines (NASDAQ:VBIV) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The firm had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.90 million. VBI Vaccines had a negative return on equity of 70.54% and a negative net margin of 1,458.97%. As a group, equities analysts anticipate that VBI Vaccines Inc will post -0.47 EPS for the current year.
In other news, major shareholder Perceptive Advisors Llc bought 20,000,000 shares of the company’s stock in a transaction dated Monday, September 23rd. The stock was bought at an average cost of $0.50 per share, for a total transaction of $10,000,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jeff Baxter purchased 150,000 shares of the business’s stock in a transaction dated Monday, September 30th. The shares were purchased at an average cost of $0.50 per share, with a total value of $75,000.00. Following the acquisition, the chief executive officer now owns 608,255 shares in the company, valued at approximately $304,127.50. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 30,212,000 shares of company stock worth $15,105,440. Corporate insiders own 10.50% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC bought a new position in VBI Vaccines in the third quarter valued at about $214,000. Sabby Management LLC acquired a new position in VBI Vaccines in the 3rd quarter valued at approximately $413,000. Virtu Financial LLC bought a new position in shares of VBI Vaccines during the third quarter valued at $122,000. State Street Corp raised its stake in shares of VBI Vaccines by 4.3% during the third quarter. State Street Corp now owns 1,495,738 shares of the biopharmaceutical company’s stock valued at $705,000 after acquiring an additional 61,829 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of VBI Vaccines by 1,488.3% during the third quarter. Tower Research Capital LLC TRC now owns 109,087 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 102,219 shares during the period. Institutional investors and hedge funds own 40.91% of the company’s stock.
About VBI Vaccines (NASDAQ:VBIV)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
Featured Article: Book Value Per Share – BVPS
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.